Advertisement

Prognostic Value of a Cell Cycle Progression Score for Men with Prostate Cancer

  • Jack CuzickEmail author
Chapter
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 202)

Abstract

A new prognostic score called the cell cycle progression or CCP score has been evaluated for predicting outcome in men with prostate cancer. The score is based on 31 cell cycle progression genes and 15 housekeeper control genes. Results on 5 cohorts have been reported. In all cases the CCP score was strongly predictive of outcome both in univariate models and in multvariate models incorporating standard factors such as Gleason grade, PSA levels and extent of disease. Two cohorts evaluated patients managed by active surveillance where the outcome was death from prostate cancer, two cohorts examined patients treated by radical prostatectomy where biochemical recurrence was the primary endpoint, and one smaller cohort looked at patients treated with radiotherapy where again biochemical recurrence was used as the endpoint. In all cases a unit change in CCP score was associated with an approximate doubling of risk of an event. These data provide strong event to support use of the CCP score to help guide clinical management.

Keywords

Prostate Cancer Cell Cycle Progression Radical Prostatectomy Gleason Score Biochemical Recurrence 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Berney DM, Gopalan A, Kudahetti S, Fisher G, Ambroisine L, Foster CS, Reuter V, Eastham J, Moller H, Kattan MW, Gerald W, Cooper C, Scardino P, Cuzick J (2009) Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic prostate group study. Br J Cancer 100(6):888–893PubMedCentralPubMedCrossRefGoogle Scholar
  2. Chao C, Chi M, Preciado M, Black MH (2013) Methylation markers for prostate cancer prognosis: a systematic review. Cancer Causes Control. Jun 25 [Epub ahead of print]Google Scholar
  3. Cooperberg MR, Hilton JF, Carroll PR (2011) The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer 117(22):5039–5046. doi: 10.1002/cncr.26169 Epub 2011 Jun 3PubMedCentralPubMedCrossRefGoogle Scholar
  4. Cooperberg MR, Simko JP, Cowan JE, Reid JE, Djalilvand A, Bhatnagar S, Gutin A, Lanchbury JS, Swanson GP, Stone S, Carroll PR (2013) Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol 31(11):1428–1434PubMedCrossRefGoogle Scholar
  5. Cuzick J, Fisher G, Kattan MW, Berney D, Oliver T, Foster CS, Moller H, Reuter V, Fearn P, Eastham J, Scardino P (2006) Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer 95(9):1186–1194Google Scholar
  6. Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, Mesher D, Speights VO, Stankiewicz E, Foster CS, Møller H, Scardino P, Warren JD, Park J, Younus A, Flake DD 2nd, Wagner S, Gutin A, Lanchbury JS, Stone S (2011) Transatlantic prostate group. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 12(3):245–255Google Scholar
  7. Cuzick J, Berney DM, Fisher G, Mesher D, Møller H, Reid JE, Perry M, Park J, Younus A, Gutin A, Foster CS, Scardino P, Lanchbury JS, Stone S (2012) Transatlantic prostate group. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer 106(6):1095–1099Google Scholar
  8. Cuzick J, Yang ZH, Fisher G, Tikishvili E, Stone S, Lanchbury JS, Camacho N, Merson S, Brewer D, Cooper CS, Clark J, Berney DM, Møller H, Scardino P, Sangale Z (2013) Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer. Br J Cancer. doi:  10.1038/bjc.2013.248. (Epub ahead of print)
  9. Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, Bergstralh EJ, Kollmeyer T, Fink S, Haddad Z, Zimmermann B, Sierocinski T, Ballman KV, Triche TJ, Black PC, Karnes RJ, Klee G, Davicioni E, Jenkins RB (2013) Discovery and Validation of a Prostate Cancer Genomic Classifier that Predicts Early Metastasis Following Radical Prostatectomy. PLoS One Jun 24;8(6):e66855. doi:  10.1371/journal.pone.0066855. Print 2013
  10. Freedland SJ, Gerber L, Reid J, Welbourn W, Tikishvili E, Park J, Younus A, Gutin A, Sangale Z, Lanchbury JS, Salama JK, Stone S (2013) Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int J Radiat Oncol Biol Phys. Jun 4. [Epub ahead of print]Google Scholar
  11. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT (1998) A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90(10):766–771PubMedCrossRefGoogle Scholar
  12. Markert EK, Mizuno H, Vazquez A, Levine AJ (2011) Molecular classification of prostate cancer using curated expression signatures. Proc Natl Acad Sci U S A 108(21276–21281):9Google Scholar
  13. Penney KL, Sinnott JA, Fall K, Pawitan Y, Hoshida Y et al (2011) mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol 29:2391–2396PubMedCrossRefGoogle Scholar
  14. Vasiljević N, Wu K, Brentnall AR, Kim DC, Thorat MA, Kudahetti SC, Mao X, Xue L, Yu Y, Shaw GL, Beltran L, Lu YJ, Berney DM, Cuzick J, Lorincz AT (2011) Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. Dis Markers 30(4):151–161. doi: 10.3233/DMA-2011-0790 PubMedCrossRefGoogle Scholar
  15. Wang K, Peng HL, Li LK (2012) Prognostic value of vascular endothelial growth factor expression in patients with prostate cancer: a systematic review with meta-analysis. Asian Pac J Cancer Prev 13(11):5665–5669PubMedCrossRefGoogle Scholar
  16. Wu CL, Schroeder BE, Ma XJ, Cutie CJ, Wu S, Salunga R, Zhang Y, Kattan MW, Schnabel CA, Erlander MG, McDougal WS (2013) Development and validation of a 32-gene prognostic index for prostate cancer progression. Proc Natl Acad Sci U S A 110(15):6121–6126. doi: 10.1073/pnas.1215870110 Epub 2013 Mar 26PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Centre for Cancer Prevention, Wolfson Institute of Preventive MedicineQueen Mary University of LondonLondonUK

Personalised recommendations